Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, bilastine (Ilaxten®) cannot be endorsed for use within NHS Wales for the symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria. |
||
|
||
Medicine details |
||
| Medicine name | bilastine (Ilaxten®) | |
| Formulation | 20 mg tablet | |
| Reference number | 1068 | |
| Indication | For the symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria. |
|
| Company | A. Menarini Farmaceutica Internazionale SRL | |
| BNF chapter | Respiratory system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 13/10/2011 | |